In 2016, the major scientific publisher Springer despaired so deeply of the rampant peer-review fraud occurring at one of their journals, Tumor Biology, that, after retracting 107 tainted articles from just four years’ worth of issues, they gave up publishing the journal and sold it off to another company.
